These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

603 related articles for article (PubMed ID: 31351504)

  • 1. Efficacy of Omalizumab in Patients with Chronic Spontaneous Urticaria and Its Association with Serum IgE Levels and Eosinophil Count.
    Tamer F; Gulru Erdogan F; Dincer Rota D; Yildirim D; Akpinar Kara Y
    Acta Dermatovenerol Croat; 2019 Jun; 27(2):101-106. PubMed ID: 31351504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the Patients with Chronic Urticaria Who Responded and Did Not Respond to Omalizumab Treatment: A Single-Center Retrospective Study.
    Cakmak ME
    Int Arch Allergy Immunol; 2022; 183(11):1209-1215. PubMed ID: 36007494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omalizumab does not lead to a distinct alteration in hematological parameters and complete blood count-derived inflammation biomarkers except for basophil count.
    Tamer F
    Cutan Ocul Toxicol; 2020 Sep; 39(3):229-232. PubMed ID: 32380865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atopy and Response to Omalizumab Treatment in Chronic Spontaneous Urticaria.
    Costa C; Esteves Caldeira L; Paulino M; Santos DF; Silva SL
    Int Arch Allergy Immunol; 2024; 185(3):260-266. PubMed ID: 38113870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of omalizumab treatment in chronic spontaneous urticaria is associated with basophil phenotypes.
    Johal KJ; Chichester KL; Oliver ET; Devine KC; Bieneman AP; Schroeder JT; MacGlashan DW; Saini SS
    J Allergy Clin Immunol; 2021 Jun; 147(6):2271-2280.e8. PubMed ID: 33713769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab.
    MacGlashan D; Saini S; Schroeder JT
    J Allergy Clin Immunol; 2021 Jun; 147(6):2295-2304.e12. PubMed ID: 33716077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What can be learned from real-world data about chronic spontaneous urticaria?
    Bakay OSK; Kacar N; Gul B; Goksin S; Gural Y
    Allergy Asthma Proc; 2024 Jul; 45(4):255-261. PubMed ID: 38982597
    [No Abstract]   [Full Text] [Related]  

  • 8. In chronic spontaneous urticaria, increased Galectin-9 expression on basophils and eosinophils is linked to high disease activity, endotype-specific markers, and response to omalizumab treatment.
    Ji J; Tang M; Zhao Y; Zhang C; Shen Y; Zhou B; Liu C; Maurer M; Jiao Q
    Allergy; 2024 Sep; 79(9):2435-2447. PubMed ID: 39021347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Total IgE and atopic status in patients with severe chronic spontaneous urticaria unresponsive to omalizumab treatment.
    Asero R; Ferrucci S; Casazza G; Marzano AV; Cugno M
    Allergy; 2019 Aug; 74(8):1561-1563. PubMed ID: 30801715
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria.
    Brás R; Esteves Caldeira L; Bernardino A; Costa C
    Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved FcεRI-Mediated CD203c Basophil Responsiveness Reflects Rapid Responses to Omalizumab in Chronic Spontaneous Urticaria.
    Oda Y; Fukunaga A; Washio K; Imamura S; Mizuno M; Hatakeyama M; Ogura K; Nishigori C
    J Allergy Clin Immunol Pract; 2021 Mar; 9(3):1166-1176.e8. PubMed ID: 32898709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice.
    Vollono L; Piccolo A; Lanna C; Esposito M; Bavetta M; Campione E; Bianchi L; Diluvio L
    Drug Des Devel Ther; 2019; 13():3181-3186. PubMed ID: 31564834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution.
    Deza G; March-Rodríguez A; Sánchez S; Ribas-Llauradó C; Soto D; Pujol RM; Gimeno R; Giménez-Arnau AM
    J Allergy Clin Immunol Pract; 2019; 7(5):1619-1626.e1. PubMed ID: 30685572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria.
    Magen E; Waitman DA; Kahan NR
    Allergy Asthma Proc; 2021 Jan; 42(1):e17-e24. PubMed ID: 33404397
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin.
    Metz M; Staubach P; Bauer A; Brehler R; Gericke J; Kangas M; Ashton-Chess J; Jarvis P; Georgiou P; Canvin J; Hillenbrand R; Erpenbeck VJ; Maurer M
    Theranostics; 2017; 7(5):1266-1276. PubMed ID: 28435464
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-life data on the effectiveness and safety of omalizumab in monotherapy or combined for chronic spontaneous urticaria: a retrospective cohort study.
    Salman A; Ergun T; Gimenez-Arnau AM
    J Dermatolog Treat; 2020 Mar; 31(2):204-209. PubMed ID: 30821591
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of chronic autoimmune urticaria with omalizumab.
    Kaplan AP; Joseph K; Maykut RJ; Geba GP; Zeldin RK
    J Allergy Clin Immunol; 2008 Sep; 122(3):569-73. PubMed ID: 18774392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind placebo-controlled trial of the effect of omalizumab on basophils in chronic urticaria patients.
    Jörg L; Pecaric-Petkovic T; Reichenbach S; Coslovsky M; Stalder O; Pichler W; Hausmann O
    Clin Exp Allergy; 2018 Feb; 48(2):196-204. PubMed ID: 29164723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful treatment of four types of chronic urticaria with anti-IgE omalizumab in the same patient.
    Nettis E; Di Leo E; Calogiuri G; Foti C; Macchia L
    Ann Allergy Asthma Immunol; 2019 Mar; 122(3):336-337. PubMed ID: 30529714
    [No Abstract]   [Full Text] [Related]  

  • 20. Experience with Omalizumab for the treatment of chronic spontaneous urticaria in a tertiary center: real life experience.
    Acar A; Gerceker Turk B; Ertam Sagduyu I; Ceylan C; Ozturk G; Unal I
    Cutan Ocul Toxicol; 2020 Sep; 39(3):249-253. PubMed ID: 32597235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.